The Corteva, Novartis, AbbVie and Heritage Medical Systems-backed cancer therapy developer priced a $304m initial public offering at the top of its range.
US-based cell therapy developer Caribou Biosciences is going public today in a $304m initial public offering representing an exit for corporate investors Corteva, AbbVie, Novartis and Heritage Medical Systems.
The company increased the number of shares in the offering from 17 million to 19 million and priced them at the top of the IPO’s $14 to $16 range. It is floating on the Nasdaq Global Select Market and the share price gives it a valuation of almost $910m.
Caribou…
